Acadia Extends Trofinetide Patent Protection to 2041
ACAD is trading near its 52-week low of $19.69 (4.3% above the low) on elevated volume (2.0× avg).
Summary
The USPTO issued a Notice of Allowance for Acadia's weight-banded dosing patent for trofinetide, extending U.S. protection to March 2041 from July 2036. This adds nearly five years of exclusivity for DAYBUE and DAYBUE STIX, the company's Rett syndrome franchise. The extension is material given DAYBUE's commercial importance and the recent remlifanserin setback. It strengthens the long-term revenue outlook for the franchise.
At the time of this announcement, ACAD was trading at $20.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $19.69 to $30.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.